A distinctive approach to therapeutic cannabis, empowering individuals

on their wellness journey

 

Dynamic and innovative certified woman-owned company within the burgeoning cannabis industry. As a vertically integrated company, we operate in all facets of the cannabis market including product development, retail, education, and research.

With an unflinching commitment to quality, RPL stands tall in the industry, delivering a comprehensive range

of natural and evidenced-based solution of top-tier cannabis products

to both medical and recreational users.

 

RPL has an exclusive Global Distribution and Licensing Agreement for 

proprietary patented Orally Disintegrating Tablet (ODT)


Buccal drug delivery is an oral administration that reaches systemic circulation via the lining of the cheek and gum.  

The buccal route avoids hepatic first-pass metabolism and enzymatic drug degradation, thus enhancing drug permeance, penetration and bioavailability

Advanced Product

Design

  • Micro-dosed based on therapeutic need

Anxiety/Sleep Issues = Low Dose

Chronic Pain = Higher Dose

Recreational  = Preference Based

  • RPL uses product innovation to          transform and create a healthcare breakthrough; customizable shape, size, flavor
  • True pharmaceutical delivery platform recognized by governing bodies in over 60 countries

Practical Research and Education

  • Cannabis as an effective pain medication and Opioid alternative
  • Clinical Research Studies and Collaborations with Major Research Institutions
  • Efficacy Based Local Initiative
  • Advise practitioners on preferred usage and capabilities supported by practical studies
  • Community-Engaged Health Professional Education

Legislative and Healthcare Initiatives

  • National approach to creating a narrative around 3rd Party Reimbursement
  • Health Insurers
  • Veterans Administration
  • Advancing cannabis as a therapeutic resource for ongoing patient care


We are thrilled to announce that RPL is expanding its horizons! In 2024, we will be opening a state-of-the-art laboratory, marking a significant milestone in our journey. This facility will be dedicated to the manufacturing and distribution of our patented, proprietary Orally Disintegrating Tablet (ODT).
Our ODT is a marvel of nanotech precision, designed to deliver peak bioavailability, ensuring optimal effectiveness with every dose. Each tablet is crafted with pharma-grade elegance, embodying the pinnacle of pharmaceutical design and functionality.

Co-Founders: Timory Ridall & Kysha Pierre-Louis